MedTrace Logo

Efficacy and Tolerability of Xalatan in Patients

NCT00950690 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1289

Last updated 2021-02-25

Study results available
· View outcomes & findings →

Summary

Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan.

Conditions

Interventions

DRUG

Xalatan 0.005% eye drops

ophthalmic solution dosed once daily for 3 months

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • Egypt
  • Saudi Arabia
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00950690 on ClinicalTrials.gov